Defensins

Defensins are cysteine-rich, disulfide-stabilised peptides split into alpha-defensins (roughly 29-35 residues, from neutrophil granules and Paneth cells) and beta-defensins (roughly 36-45 residues, from epithelial surfaces). No single sequence length or molecular weight applies to the family, which is why those fields are null here. Their primary antimicrobial mechanism is electrostatic: the net positive charge draws them to anionic bacterial membranes, where they insert and form pores, killing bacteria, fungi and enveloped viruses without a specific molecular target and therefore with low resistance development. Their second role is immunological - HBD-2 and HBD-3 act as chemoattractants for immature dendritic cells and memory T-cells via CCR6, and HNPs modulate cytokine release, complement activation and wound repair. They are also implicated in disease: Paneth cell alpha-defensin deficiency is a feature of ileal Crohn's disease, and beta-defensin gene copy number correlates with psoriasis risk.

Targets: Anionic microbial membranes, CCR6, Dendritic cell and T-cell chemotaxis, Complement and cytokine modulation

• · There is no approved or conventionally dosed defensin product. What reaches consumers are cosmetic 'defensin' skin preparations using synthetic analogues at undisclosed concentrations, and those should not be confused with the endogenous peptides described here. Anyone wanting a purchasable host-defence peptide in practice uses LL-37 instead, which at least has a defined single sequence.

Work out your exact syringe units →

• commonCytotoxicity to host cells at high concentrations— The membrane-disrupting mechanism is not perfectly selective - this is the main reason defensins have failed as systemic drugs.
• uncommonLocal irritation with topical preparations
• uncommonPro-inflammatory effects— Elevated beta-defensin activity is associated with psoriasis severity rather than benefit.

• No systemic human use is defined, so no meaningful contraindication list can be given. Treat any product claiming systemic defensin dosing as unvalidated.

• synergyll-37 — Cathelicidin and defensins act synergistically at mucosal surfaces in vitro; LL-37 is the practically available member of this space.
• synergyVitamin D — Vitamin D receptor signalling directly upregulates endogenous cathelicidin and beta-defensin expression - raising your own defensins is more actionable than injecting them.

• · No monitoring applies since no established therapeutic use exists.

No approved defensin drug exists. Synthetic analogues appear in cosmetic skincare; research-grade peptides are laboratory reagents.

• Ganz, defensins: antimicrobial peptides of innate immunity (Nature Reviews Immunology 2003) (review)
• Reduced Paneth cell alpha-defensin expression in ileal Crohn's disease (preclinical)
• Beta-defensin gene copy number and psoriasis susceptibility (other)

The antimicrobial mechanism is electrostatic and physical rather than target-based, and that is the source of both the appeal and the failure. Net positive charge draws defensins to the anionic phospholipids and lipopolysaccharide of microbial membranes; host cell membranes, which are enriched in zwitterionic phosphatidylcholine and cholesterol on the outer leaflet, are relatively spared. Once bound, the peptides insert and form pores or disrupt membrane integrity. Because there is no specific molecular target, resistance is slow to develop - a bacterium would have to rebuild its membrane chemistry. The problem is that the same electrostatics are shielded by salt: at physiological sodium concentration most defensins lose much of their activity, which is why they work well in a low-salt assay and poorly in a patient. Their second role is immunological and arguably more important therapeutically: HBD-2 and HBD-3 act as chemoattractants for immature dendritic cells and memory T-cells through CCR6, and HNPs modulate cytokine release, complement activation and wound repair. That makes defensins a bridge between innate and adaptive immunity rather than merely antibiotics. The disease genetics are instructive in both directions: reduced Paneth cell alpha-defensin expression is a feature of ileal Crohn's disease, so too little is harmful; and beta-defensin gene copy number correlates with psoriasis risk, so too much is also harmful. That bidirectional harm is the strongest single argument against treating 'more defensins' as a goal.

The failure mode is buying something that does not exist as a therapeutic. There is no approved defensin drug, no established dose, no route and no human pharmacokinetics, and research-grade individual defensins are laboratory reagents priced and packaged as such. If someone is selling a systemic defensin product with a suggested dose, the number is invented. Beyond the commercial problem, the pharmacological reasons this class failed are worth knowing because they will not be solved by a vendor: cytotoxicity to host cells at the concentrations needed for reliable killing, loss of activity at physiological salt concentration, cost of synthesising a triple-disulfide-bonded peptide with correct connectivity, and a short in vivo lifetime. There is also a real direction-of-effect problem - elevated beta-defensin gene copy number correlates with psoriasis severity, so more is not automatically better even in someone's own tissue.

• Anionic microbial membranes (lipopolysaccharide, lipoteichoic acid, anionic phospholipids) — Electrostatic rather than a defined binding constant; activity is substantially inhibited at physiological salt concentrations

  Membrane insertion, permeabilisation and pore formation, killing bacteria, fungi and enveloped viruses. No specific molecular target, hence very low resistance development.

• CCR6 — Not quantified here

  HBD-2 and HBD-3 act as chemoattractants for immature dendritic cells and memory T-cells, linking innate detection to adaptive priming. This is arguably the more therapeutically interesting activity.

• Complement and cytokine networks — Not applicable

  HNPs modulate complement activation and cytokine release, and contribute to wound repair signalling.

• Host cell membranes at high concentration — Not applicable - off-target consequence of the same mechanism

  Cytotoxicity. The membrane selectivity is relative, not absolute, and this is the principal reason defensins failed as systemic drugs.

Not established for any therapeutic preparation, because none exists. Endogenously, defensin release from neutrophil granules is immediate on degranulation and Paneth cell secretion follows bacterial exposure within minutes to hours - but that is physiology, not a dosing timeline. If you are pursuing the vitamin D route to raising endogenous expression, allow eight to twelve weeks for 25-hydroxyvitamin D levels to stabilise before expecting any downstream change.

There is no purchasable defensin to stack. The practically useful version of this entry is a redirect: if you want a host-defence peptide you can actually obtain and dose, LL-37 is the cathelicidin with a single defined sequence and an existing research market, and defensins and cathelicidin act synergistically at mucosal surfaces in vitro. If you want to raise your own defensins, vitamin D receptor signalling upregulates both beta-defensin and cathelicidin expression directly, and correcting a deficiency is a real intervention with a real mechanism. Anything sold as an injectable or oral 'defensin' product should be treated as unvalidated - cosmetic skincare using synthetic defensin-adjacent analogues is a separate category and should not be confused with the endogenous peptides described here.

Defensins are in this dataset as a template class rather than a usable compound, and the comparison that matters is against LL-37, which is the member of the host-defence peptide space that people actually obtain. LL-37 has one defined sequence, no disulfide connectivity problem, and an existing research market; defensins have neither a single sequence nor a route. Against lactoferrin, which also has direct antimicrobial membrane activity via its lactoferricin fragment, lactoferrin is orally available, cheap, and has actual randomised trials - it is the practical version of this idea. Against everything else in this class, defensins are the clearest illustration of a recurring pattern: textbook-level established biology that has repeatedly failed to become a drug, for reasons that are pharmacological rather than commercial.

Deliberately null. There is no therapeutic defensin product to price. Research-grade individual peptides are sold in microgram to milligram quantities as laboratory reagents at prices that bear no relation to a therapeutic course.

• ?No pharmacokinetic data exist for any defensin as a therapeutic, so every quantitative field is null.
• ?The sequence field is empty and unverified because the family has no single sequence. Individual members have well-established sequences available from UniProt but were not transcribed here.
• ?Binding affinities for the CCR6 interaction and for microbial membranes were not verified against primary sources in this session.
• ?The relative importance of the direct antimicrobial role versus the chemotactic and immunomodulatory role in human physiology is genuinely debated and not settled.
• ?The extent to which salt sensitivity in vitro reflects actual behaviour at mucosal surfaces in vivo is contested.
• ?Cosmetic products marketed as containing 'defensins' typically use synthetic analogues at undisclosed concentrations and have no established relationship to the endogenous peptides described here.
• ?The trials and titration arrays are empty because no human therapeutic trial or dosing regimen exists for any defensin.

• Defensins: antimicrobial peptides of innate immunity Ganz T, Nature Reviews Immunology, 2003 · PMID 12949495

  The standard reference for the entire family - structure, classes, mechanism, and the immunological bridging role. If you read one paper on defensins, this is it.